Compare HPI & DNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HPI | DNA |
|---|---|---|
| Founded | N/A | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 431.6M | 458.6M |
| IPO Year | 2002 | 2020 |
| Metric | HPI | DNA |
|---|---|---|
| Price | $15.47 | $6.79 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 43.1K | ★ 1.2M |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 46.49 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $170,155,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $15.26 | $5.37 |
| 52 Week High | $17.61 | $17.58 |
| Indicator | HPI | DNA |
|---|---|---|
| Relative Strength Index (RSI) | 22.76 | 42.95 |
| Support Level | $15.26 | $6.38 |
| Resistance Level | $16.36 | $7.10 |
| Average True Range (ATR) | 0.13 | 0.43 |
| MACD | -0.03 | 0.02 |
| Stochastic Oscillator | 1.69 | 16.10 |
John Hancock Preferred Income Fund is a closed-end, diversified management investment company. Its primary investment objective is to provide a high-level of current income consistent with preservation of capital. The fund's secondary investment objective is to provide growth of capital to the extent consistent with its primary investment objective. It seeks to achieve its investment objectives by investing in securities that may be undervalued relative to similar securities in the marketplace. The fund's principal investment strategies include investing a majority of its assets in preferred stocks and other preferred securities. Its portfolio composition consists of U.S preferred securities, common stocks, foreign preferred securities, corporate bonds, and short-term investments.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering engaged in providing biological R&D services for customers across a range of industries and Biosecurity that provides services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.